Quoin Pharmaceuticals (QNRX) Financials

$6.74

$0.23 (3.53%)

As on 02-Sep-2026 16:00EDT

Market cap

$12 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

2.6

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	--	--	--	--	--	--
Cost of Revenue	0.08	0.10	0.10	0.10	0.10	0.10
Gross Profit	-0.08	-0.10	-0.10	-0.10	-0.10	-0.10
Operating Expenses	19.21	16.29	9.53	9.38	9.26	6.06
Operating Profit (EBIT)	-19.24	-16.29	-9.53	-9.38	-9.26	-6.06
Other Income	--	--	--	--	--	--
Profit before Tax	-18.76	-15.80	-8.96	-8.69	-9.38	-21.46
Provision for Tax	--	--	-8,953.47	0.02	-0.10	-12.94
Profit after Tax (Net Income)	-18.76	-15.80	-8.96	-8.69	-9.38	-21.46
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-9.45	-21.46

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	3.93	13.12	9.20	5.66	7.41	0.66
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	1.42	1.72	2.32	2.92	3.52	4.12
Current Liabilities	6.61	5.55	4.18	3.58	3.53	4.58
Total Liabilities	18.58	20.39	15.71	12.17	14.46	9.36

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	0.33	0.38	0.78	0.88	1.09	1.16
Current Assets	11.64	20.01	14.93	11.29	13.37	8.20
Total Assets	23.61	20.39	15.71	12.17	14.46	9.36
Total Debt*	--	--	--	--	--	--
Net Current Assets	--	14.46	10.75	7.70	9.84	3.62

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-13.54	-7.86	-7.86	-8.48	-5.72
Cash Flow from Investing Activities	--	-4.28	-1.89	2.19	-10.15	-0.63
Cash from Financing Activities	--	18.01	10.97	5.22	14.01	13.50
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-14.88	-10.55	-48.06	-308.03	-815.78	--
Cash EPS ($)	--	-10.48	-47.52	-304.35	-806.74	--
Adjusted Book Value ($)	--	8.76	49.35	200.85	644.07	--
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-9.04	-42.13	-278.88	-737.45	--
Free Cash Flow per Share ($)	--	-9.04	-42.13	-278.88	-759.19	--

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	-141.59	-120.55	-132.92	-232.68	906.18
ROE (%)	-220.00	-141.59	-120.55	-132.92	-232.68	721.40
ROA (%)	-101.79	-87.56	-64.30	-65.25	-78.79	-399.87
EBIT Margin (%)	--	--	--	--	--	--
Net Margin (%)	--	--	--	--	--	--
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	--	--	--	--	--	--
EBIT Growth (%)	-54.88	-76.34	-3.18	-0.22	57.45	-1,119.88
Net Profit Growth (%)	-54.14	-76.34	-3.18	7.41	56.29	-924.29
EPS Growth (%)	64.24	0.78	0.84	0.62	--	--
Book Value Growth (%)	-54.86	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	--	-1.37	-0.01	-0.02	0.00	--
Price / Book Value	2.63	1.65	0.01	0.02	0.00	--
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-0.42	242.69	1.57	1.23	1.50	0.37
Close Price ($)	4.84	14.43	22.77	171.68	7,156.80	114,660.00
High Price ($)	41.80	41.80	216.30	14,212.80	148,050.00	2,237,760.00
Low Price ($)	3.25	5.05	14.88	127.40	5,594.40	107,100.00
Market Cap ($ Cr)	12.29	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	--	--	--	--	--
Short term debt to equity ratio	--	--	--	--	--	--
Current Ratio	1.76	3.61	3.57	3.15	3.79	1.79
Quick Ratio	1.76	--	--	--	--	--
Interest Coverage	--	--	--	--	-12.14	-18.68

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	--	--	--	--	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	3,927.99	2,603.27	1,998.82	2,694.11	3,238.85
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.